⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16877827 | 0.83 | L3MBTL1 (0.36) | — | |
| SCHEMBL10752069 | 0.81 | — | — | |
| SCHEMBL1254524 | 0.81 | — | — | |
| SCHEMBL29464927 | 0.81 | — | — | |
| SCHEMBL30511 | 0.81 | — | — | |
| SCHEMBL245244 | 0.81 | — | — | |
| SCHEMBL4069679 | 0.81 | MBTD1 (0.32) | — | |
| SCHEMBL9047529 | 0.81 | — | — | |
| SCHEMBL17681496 | 0.81 | — | — | |
| SCHEMBL1829769 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | claimed |
| US-20240343736-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | claimed |
| WO-2024206747-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| EP-4298095-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | Sperogenix Therapeutics Limited (HK) | 2024-01-03 | — | — | EP | claimed |
| WO-2022162606-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | SPEROGENIX THERAPEUTICS LIMITED (CN) | 2022-08-04 | — | — | WO | claimed |
| US-12577219-B2 | Macrolide brefeldin a ester derivatives and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2026-03-17 | — | — | US | disclosed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250171440-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |